Merck and Luminex Corp. have signed a collaboration and license agreement to develop a companion diagnostic to help screen patients for Merck’s clinical development program for MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck’s lead candidate for Alzheimer’s disease (AD). Financial terms were not disclosed.   Luminex will be responsible for development, regulatory submission and commercialization of the candidate companion dia...